Navigation Links
VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
Date:5/22/2008

Rigel Pharmaceuticals CMO to Add Valuable Clinical Development Expertise

SAN DIEGO, May 22 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the appointment of Dr. Elliott Grossbard to its Board of Directors.

"We are pleased to have Elliott join our Board of Directors," said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. "We look forward to working closely with Elliott as we advance the first selective TLR8 agonists into the clinic this fall. His insights and experience will be invaluable as we embark into clinical development in 2008."

"I am pleased to be joining the Board of VentiRx," said Dr. Grossbard. "VentiRx is a rapidly emerging company equipped with a talented management team and very interesting clinical development candidates in oncology and allergy. I look forward to working with management and the other members of the Board to advance these novel molecules and build a successful company."

"We welcome Elliott to the Board," said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx. "Elliott brings to VentiRx a long history of clinical development expertise in therapeutic areas that are vital for us."

Dr. Grossbard is Executive Vice President and Chief Medical Officer at Rigel Pharmaceuticals (Nasdaq: RIGL). He joined Rigel as Senior Vice President of Medical Development in April 2002. Prior to joining Rigel, Dr. Grossbard was Vice President, Clinical Affairs for Avigen Inc., and he served as Senior Vice President of Development and Vice President of Medic
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
2. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
3. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
4. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
5. Transdel Pharmaceuticals Closes $4 Million Financing
6. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sagent Pharmaceuticals Provides US$20,000 in Aid to Earthquake-Devastated Areas in Central China
8. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
9. Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
10. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- The Board of Directors of BD (Becton, Dickinson and ... dividend of 54.5 cents per common share payable on September ... The indicated annual dividend rate is $2.18 per share. ... medical technology company that partners with customers and stakeholders to ... needs. Our innovative solutions are focused on improving drug delivery, ...
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST) ... a new design for an atomic clock that ... a microcomb. , The microcomb clock, featured on ... new journal Optica ,* is the first ... its accurate conversion of optical frequencies to lower ...
(Date:7/22/2014)... a senior lecturer in mechanical engineering at the University ... the Year by the North Texas section of the ... more than 130,000 members in 158 countries who develop ... assist the engineering community, benefiting the world. , ASME ... of Professional Engineers honors banquet. Baughn retired as an ...
(Date:7/22/2014)... July 22, 2014 Nuclear reactors are ... produced by controlled fission chain reaction in nuclear reactors ... is used to drive a power- generating turbine. Currently ... the world’s total electricity production. Nuclear reactor market is ... construction, planned and proposed nuclear reactor projects. , Early ...
Breaking Biology Technology:'Comb on a chip' powers new NIST/Caltech atomic clock design 2UT Dallas professor receives Engineer of the Year award 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... N.C., Jan. 5, 2012 Tengion, Inc. (NASDAQ: ... medicine, today announced it has completed the relocation ... to the Company,s existing facility in Winston-Salem, North ... previously announced restructuring, which was designed to fund ...
... SARASOTA, Fla., Jan. 5, 2012  George Miller developed an ... His doctor sent cell scrapings to a pathologist, and ... TMD Limited, a medical tourism company, squamous cell carcinoma ... humans and other animals.  Squamous cell ...
... Jan. 5, 2012  AtheroNova, (OTCQB: AHRO) ("AtheroNova"), a biotech company ... atherosclerotic plaque, announced today that it has appointed Johan M. ... Directors of the Company effective January 3, 2012. Mr. Spoor ... and Medical Committees of the Board. "I ...
Cached Biology Technology:Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 2Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 3Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina 4Squamous Cell Cancer Responds to SPDT Therapy 2Squamous Cell Cancer Responds to SPDT Therapy 3Squamous Cell Cancer Responds to SPDT Therapy 4AtheroNova Announces a New Board Member 2AtheroNova Announces a New Board Member 3
(Date:7/23/2014)... HOLE, MA -- What do mollusks, starfish, and ... marine habitat, they are all calcifiersorganisms that use ... skeletons and shells for stability and protection. , ... , published by the Marine Biological Laboratory, addresses ... composition changes worldwide. , As atmospheric carbon dioxide ...
(Date:7/23/2014)... the principal bacteria that cause dental caries, has ... time, possibly coinciding with dietary change linked to ... in a study by researchers from the Universitat ... de Genmica para la Biodiversidad (National Laboratory of ... first time, have sequenced genetic material from this ...
(Date:7/23/2014)... popular culinary herbs oregano and rosemary are packed with ... work in much the same way as prescription anti-diabetic ... ACS, Journal of Agricultural and Food Chemistry , ... a difference, and they also identified which compounds contribute ... de Mejia and colleagues point out that in 2012, ...
Breaking Biology News(10 mins):Calcification in changing oceans explored in special issue of The Biological Bulletin 2Ancient genetic material from caries bacterium obtained for the first time 2
... total energy used in the USA is taken up in ... comes from non-renewable energy sources which are in short supply. ... reducing this significant fuel consumption in the US food system ... the Springer journal Human Ecology , David Pimentel and ...
... CO, USA GEOLOGY topics include confirmation that ... a blowout in the Banjar Panji-1 well; evidence of the ... analysis of Yellowstone,s hotspot; and GPS measurements that show why ... GSA Today ,s science article studies the impact of Glen ...
... medicines and the introduction of new anti-arthritis drugs ... (RA), according to guidelines issued by the American ... the University of Alabama at Birmingham (UAB). ... in the UAB Division of Clinical Immunology and ...
Cached Biology News:Why eating less can help the environment 2August 2008 Geology and GSA Today media highlights 2August 2008 Geology and GSA Today media highlights 3August 2008 Geology and GSA Today media highlights 4August 2008 Geology and GSA Today media highlights 5August 2008 Geology and GSA Today media highlights 6August 2008 Geology and GSA Today media highlights 7August 2008 Geology and GSA Today media highlights 8August 2008 Geology and GSA Today media highlights 9August 2008 Geology and GSA Today media highlights 10August 2008 Geology and GSA Today media highlights 11August 2008 Geology and GSA Today media highlights 12New guidelines for treating rheumatoid arthritis 2
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Rabbit polyclonal to TetR ( Abpromise for all tested applications). Antigen: Synthetic peptide: AQKLGVEQPTLYWHVKNKR, corresponding to amino acids 31 - 49 of TetR...
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
Biology Products: